22 results on '"Grazia Valsecchi, Maria"'
Number of results to display per page
Search Results
2. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial
- Author
-
Biondi, Andrea, Gandemer, Virginie, De Lorenzo, Paola, Cario, Gunnar, Campbell, Myriam, Castor, Anders, Pieters, Rob, Baruchel, André, Vora, Ajay, Leoni, Veronica, Stary, Jan, Escherich, Gabriele, Li, Chi-Kong, Cazzaniga, Giovanni, Cavé, Hélène, Bradtke, Jutta, Conter, Valentino, Saha, Vaskar, Schrappe, Martin, and Grazia Valsecchi, Maria
- Published
- 2018
- Full Text
- View/download PDF
3. P374: THROMBOTIC EVENTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA: EXPERIENCE OF ITALIAN AIEOP CENTERS (2009-2017)
- Author
-
Mattera, Raffaele, primary, Caterina Putti, Maria, additional, Biffi, Alessandra, additional, Parasole, Rosanna, additional, Conter, Valentino, additional, Rizzari, Carmelo, additional, Grazia Valsecchi, Maria, additional, Silvestri, Daniela, additional, Biondi, Andrea, additional, Locatelli, Franco, additional, Barisone, Elena, additional, Micalizzi, Concetta, additional, Mina, Tommaso, additional, and Kiren, Valentina, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial
- Author
-
Morici, N, Podda, G, Birocchi, S, Bonacchini, L, Merli, M, Trezzi, M, Massaini, G, Agostinis, M, Carioti, G, Saverio Serino, F, Gazzaniga, G, Barberis, D, Antolini, L, Grazia Valsecchi, M, Cattaneo, M, Morici, Nuccia, Podda, GianMarco, Birocchi, Simone, Bonacchini, Luca, Merli, Marco, Trezzi, Michele, Massaini, Gianluca, Agostinis, Marco, Carioti, Giulia, Saverio Serino, Francesco, Gazzaniga, Gianluca, Barberis, Daniela, Antolini, Laura, Grazia Valsecchi, Maria, Cattaneo, Marco, Morici, N, Podda, G, Birocchi, S, Bonacchini, L, Merli, M, Trezzi, M, Massaini, G, Agostinis, M, Carioti, G, Saverio Serino, F, Gazzaniga, G, Barberis, D, Antolini, L, Grazia Valsecchi, M, Cattaneo, M, Morici, Nuccia, Podda, GianMarco, Birocchi, Simone, Bonacchini, Luca, Merli, Marco, Trezzi, Michele, Massaini, Gianluca, Agostinis, Marco, Carioti, Giulia, Saverio Serino, Francesco, Gazzaniga, Gianluca, Barberis, Daniela, Antolini, Laura, Grazia Valsecchi, Maria, and Cattaneo, Marco
- Abstract
Background: It is uncertain whether higher doses of anticoagulants than recommended for thromboprophylaxis are necessary in COVID-19 patients hospitalized in general wards. Methods: This is a multicentre, open-label, randomized trial performed in 9 Italian centres, comparing 40 mg b.i.d. versus 40 mg o.d. enoxaparin in COVID-19 patients, between April 30 2020 and April 25 2021. Primary efficacy outcome was in-hospital incidence of venous thromboembolism (VTE): asymptomatic or symptomatic proximal deep vein thrombosis (DVT) diagnosed by serial compression ultrasonography (CUS), and/or symptomatic pulmonary embolism (PE) diagnosed by computed tomography angiography (CTA). Secondary endpoints included each individual component of the primary efficacy outcome and a composite of death, VTE, mechanical ventilation, stroke, myocardial infarction, admission to ICU. Safety outcomes included major bleeding. Results: The study was interrupted prematurely due to slow recruitment. We included 183 (96%) of the 189 enrolled patients in the primary analysis (91 in b.i.d., 92 in o.d.). Primary efficacy outcome occurred in 6 patients (6.5%, 0 DVT, 6 PE) in the o.d. group and 0 in the b.id. group (ARR 6.5, 95% CI: 1.5–11.6). The absence of concomitant DVT and imaging characteristics suggests that most pulmonary artery occlusions were actually caused by local thrombi rather than PE. Statistically nonsignificant differences in secondary and safety endpoints were observed, with two major bleeding events in each arm. Conclusions: No DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis. Pulmonary artery occlusions developed only in the o.d. group. Our trial is underpowered and with few events.
- Published
- 2022
5. Enoxaparin for thromboprophylaxis in hospitalized COVID‐19 patients: The X‐COVID‐19 Randomized Trial
- Author
-
Morici, Nuccia, primary, Podda, GianMarco, additional, Birocchi, Simone, additional, Bonacchini, Luca, additional, Merli, Marco, additional, Trezzi, Michele, additional, Massaini, Gianluca, additional, Agostinis, Marco, additional, Carioti, Giulia, additional, Saverio Serino, Francesco, additional, Gazzaniga, Gianluca, additional, Barberis, Daniela, additional, Antolini, Laura, additional, Grazia Valsecchi, Maria, additional, and Cattaneo, Marco, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
- Author
-
Stutterheim, Janine, primary, De Lorenzo, Paola, additional, Van Der Sluis, Inge M., additional, Alten, Julia, additional, Ancliffe, Philip, additional, Attarbaschi, Andishe, additional, Aversa, Luis Alberto, additional, Boer, Judith M., additional, Biondi, Andrea, additional, Brethon, Benoit, additional, Diaz, Paulina, additional, Gazzaniga, Giovanni, additional, Escherich, Gabriele, additional, Ferster, Alina, additional, Kotecha, Rishi S, additional, Lausen, Birgitte, additional, Leung, Alex WK, additional, Locatelli, Franco, additional, Silverman, Lewis B., additional, Stary, Jan, additional, Szczepanski, Tomasz, additional, Van Der Velden, Vincent H.J., additional, Vora, Ajay, additional, Zuna, Jan, additional, Schrappe, Martin, additional, Grazia Valsecchi, Maria, additional, and Pieters, Rob, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Intercontinental collaboration in clinical trials for children and adolescents with cancer—A systematic review by ACCELERATE
- Author
-
Rojas, Teresa, primary, Pearson, Andrew J., additional, Scobie, Nicole, additional, Knox, Leona, additional, Wariabharaj, Darshan, additional, Kearns, Pamela, additional, Vassal, Gilles, additional, Reaman, Gregory, additional, Alonzo, Todd, additional, Biondi, Andrea, additional, Brodeur‐Robb, Kathy, additional, Rojas, Teresa, additional, Fouladi, Maryam, additional, Gross, Thomas, additional, Hunger, Stephen, additional, McCowage, Geoff, additional, Pappo, Alberto, additional, Schrappe, Martin, additional, Grazia Valsecchi, Maria, additional, Weigel, Brenda, additional, Wejbora, Peter, additional, Whitlock, James, additional, Zwaan, Michel, additional, Buenger, Vickie, additional, Ludwinski, Donna, additional, Barry, Elly, additional, Neville, Kathleen, additional, Sharma, Anjali, additional, and Karres, Dominik, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Infant T‐cell acute lymphoblastic leukaemia with t(6;7) ( TCRB‐MYB ) translocation
- Author
-
Ramdeny, Pemantah Sandheeah, primary, Mullanfroze, Khushnuma, additional, Lorenzo, Paola, additional, Grazia Valsecchi, Maria, additional, Meijerink, Jules, additional, Pieters, Rob, additional, Baruchel, Andre, additional, and Vora, Ajay, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia
- Author
-
Andrés-Jensen, Liv, primary, Attarbaschi, Andishe, additional, Bardi, Edit, additional, Barzilai-Birenboim, Shlomit, additional, Bhojwani, Deepa, additional, Hagleitner, Melanie M, additional, Halsey, Christina, additional, Harila-Saari, Arja, additional, van Litsenburg, Raphaele R L, additional, Hudson, Melissa M, additional, Jeha, Sima, additional, Kato, Motohiro, additional, Kremer, Leontien, additional, Mlynarski, Wojciech, additional, Möricke, Anja, additional, Pieters, Rob, additional, Piette, Caroline, additional, Raetz, Elizabeth, additional, Ronceray, Leila, additional, Toro, Claudia, additional, Grazia Valsecchi, Maria, additional, Vrooman, Lynda M, additional, Weinreb, Sigal, additional, Winick, Naomi, additional, Schmiegelow, Kjeld, additional, Adams, Madeline R, additional, Andres-Jensen, Liv, additional, Baust, Katja, additional, Boesten, Tineke, additional, Calaminus, Gabriele, additional, Conyers, Rachel, additional, Darlington, Anne-Sophie, additional, de Ville, Maëlle, additional, Escherich, Gabriele, additional, Hagleitner, Melanie, additional, Hou, Jen-Yin, additional, Huang, Ting-Huan, additional, Hudson, Melissa, additional, Jenney, Meriel, additional, Krawczuk-Rybak, Maryna, additional, Kremer, Leontine, additional, Lautem, Melchior, additional, Liu, Hse-Che, additional, Lopez Lopez, Elixabet, additional, Mateos, Marion, additional, Muszynska-Roslan, Katarzyna, additional, Niinimaki, Riitta, additional, Trahair, Toby, additional, Valsecchi, Maria Grazia, additional, van der Sluis, Inge, additional, van Litsenburg, Raphaële, additional, Vrooman, Lynda, additional, Wiener, Andreas, additional, Yano, Michihiro, additional, Yeh, Ting-Chi, additional, and Zapotocka, Ester, additional
- Published
- 2021
- Full Text
- View/download PDF
10. HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia
- Author
-
Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Josep Carreras Leukemia Foundation, European Commission, Ministerio de Economía y Competitividad (España), Fundación Unoentrecienmil, Fundación Leo Messi, Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, Barrios, Oriol de, Galaras, Alexandros, Trincado, Juan L., Azagra, Alba, Collazo, Olga, Meler, Ainara, Agraz-Doblas, Antonio, Bueno, Clara, Ballerini, Paola, Cazzaniga, Giovanni, Stam, Ronald W., Varela, Ignacio, Lorenzo, Paola De, Grazia Valsecchi, Maria, Hatzis, Pantelis, Menéndez, Pablo, Parra, Maribel, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Josep Carreras Leukemia Foundation, European Commission, Ministerio de Economía y Competitividad (España), Fundación Unoentrecienmil, Fundación Leo Messi, Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, Barrios, Oriol de, Galaras, Alexandros, Trincado, Juan L., Azagra, Alba, Collazo, Olga, Meler, Ainara, Agraz-Doblas, Antonio, Bueno, Clara, Ballerini, Paola, Cazzaniga, Giovanni, Stam, Ronald W., Varela, Ignacio, Lorenzo, Paola De, Grazia Valsecchi, Maria, Hatzis, Pantelis, Menéndez, Pablo, and Parra, Maribel
- Published
- 2021
11. Enoxaparin for thromboprophylaxis in hospitalized COVID‐19 patients: The X‐COVID‐19 Randomized Trial.
- Author
-
Morici, Nuccia, Podda, GianMarco, Birocchi, Simone, Bonacchini, Luca, Merli, Marco, Trezzi, Michele, Massaini, Gianluca, Agostinis, Marco, Carioti, Giulia, Saverio Serino, Francesco, Gazzaniga, Gianluca, Barberis, Daniela, Antolini, Laura, Grazia Valsecchi, Maria, and Cattaneo, Marco
- Subjects
PULMONARY embolism ,COVID-19 ,ENOXAPARIN ,VENOUS thrombosis ,ARTIFICIAL respiration ,HOSPITAL patients ,DRUG-eluting stents ,PULMONARY artery - Abstract
Background: It is uncertain whether higher doses of anticoagulants than recommended for thromboprophylaxis are necessary in COVID‐19 patients hospitalized in general wards Methods: This is a multicentre, open‐label, randomized trial performed in 9 Italian centres, comparing 40 mg b.i.d. versus 40 mg o.d. enoxaparin in COVID‐19 patients, between April 30 2020 and April 25 2021. Primary efficacy outcome was in‐hospital incidence of venous thromboembolism (VTE): asymptomatic or symptomatic proximal deep vein thrombosis (DVT) diagnosed by serial compression ultrasonography (CUS), and/or symptomatic pulmonary embolism (PE) diagnosed by computed tomography angiography (CTA). Secondary endpoints included each individual component of the primary efficacy outcome and a composite of death, VTE, mechanical ventilation, stroke, myocardial infarction, admission to ICU. Safety outcomes included major bleeding. Results: The study was interrupted prematurely due to slow recruitment. We included 183 (96%) of the 189 enrolled patients in the primary analysis (91 in b.i.d., 92 in o.d.). Primary efficacy outcome occurred in 6 patients (6.5%, 0 DVT, 6 PE) in the o.d. group and 0 in the b.id. group (ARR 6.5, 95% CI: 1.5–11.6). The absence of concomitant DVT and imaging characteristics suggests that most pulmonary artery occlusions were actually caused by local thrombi rather than PE. Statistically nonsignificant differences in secondary and safety endpoints were observed, with two major bleeding events in each arm. Conclusions: No DVT developed in COVID‐19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis. Pulmonary artery occlusions developed only in the o.d. group. Our trial is underpowered and with few events. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Mechanical Ventilation in COVID-19 Patients: Insights into the Role of Age and Frailty from a Multicentre Observational Study.
- Author
-
Ecarnot, Fiona, Rebora, Paola, Focà, Emanuele, Zucchelli, Alberto, Citerio, Giuseppe, Grazia Valsecchi, Maria, Marengoni, Alessandra, and Bellelli, Giuseppe
- Subjects
COVID-19 pandemic ,FRAGILITY (Psychology) ,AGE groups ,HOSPITAL care - Abstract
In patients with COVID-19, frailty has been shown to better predict outcomes than age alone. We investigated factors associated with mechanical ventilation (MV) during hospitalization for COVID-19 among older adults in a multicentre study during the first two waves in Italy. Using data from the FRACOVID project, we included consecutive patients admitted to the participating centres during the first and second waves. We recorded sociodemographics, comorbidities, time since symptom onset, ventilatory support at admission, and chest X-ray findings. Frailty was assessed using a frailty index (FI). Results are reported as hazard ratios (HR) with 95%CI. 1,344 patients were included; 487 females (36.2%), median age 68 (56; 79) years; 52.4% had hypertension, 10.6% had chronic obstructive pulmonary disease, 15.2% were obese. Median FI was 0.088 (0.03, 0.20), and 67% had bilateral consolidations at admission. Median time since symptom onset was 7 days (4, 10). During hospitalization, 47 patients (3.6%, 95%CI 0.33-13.6%) received MV. Multivariable Cox regression analysis found that the likelihood of intubation decreased with increasing age (HR 0.945 (95%CI 0.921-0.969), p<0.0001), while heart rate >110bpm (HR 3.429 (95%CI 1.583-7.429), p=0.0018), and need for continuous positive airway pressure (CPAP) at admission (HR 2.626 (95%CI 1.330-5.186), p=0.0054) were significantly associated with a greater likelihood of intubation. Older patients are less likely to receive intubation, while those with heart rate >110 bpm and need for CPAP at admission are more likely to receive MV during hospitalization for COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
- Author
-
Stutterheim, Janine, primary, van der Sluis, Inge M., additional, De Lorenzo, Paola, additional, Alten, Julia, additional, Ancliff, Philip, additional, Attarbaschi, Andishe, additional, Brethon, Benoit, additional, Biondi, Andrea, additional, Campbell, Myriam, additional, Cazzaniga, Giovanni, additional, Escherich, Gabriele, additional, Ferster, Alina, additional, Kotecha, Rishi Sury, additional, Lausen, Birgitte, additional, Li, Chi Kong, additional, Lo Nigro, Luca, additional, Locatelli, Franco, additional, Marschalek, Rolf, additional, Schrappe, Martin, additional, Stary, Jan, additional, Vora, Ajay, additional, Zuna, Jan, additional, Van Der Velden, Vincent H.J., additional, Szczepanski, Tomasz, additional, Grazia Valsecchi, Maria, additional, and Pieters, Rob, additional
- Published
- 2020
- Full Text
- View/download PDF
14. Intercontinental collaboration in clinical trials for children and adolescents with cancer—A systematic review by ACCELERATE.
- Author
-
de Rojas, Teresa, Pearson, Andrew J., Scobie, Nicole, Knox, Leona, Wariabharaj, Darshan, Kearns, Pamela, Vassal, Gilles, Reaman, Gregory, Alonzo, Todd, Biondi, Andrea, Brodeur‐Robb, Kathy, Fouladi, Maryam, Gross, Thomas, Hunger, Stephen, McCowage, Geoff, Pappo, Alberto, Schrappe, Martin, Grazia Valsecchi, Maria, Weigel, Brenda, and Wejbora, Peter
- Subjects
CLINICAL trials ,CHILDHOOD cancer ,MEDICAL research ,CARCINOGENESIS ,PEDIATRIC oncology - Abstract
Background: Since pediatric cancer drug development is a global enterprise, we sought to provide an overview of the landscape of intercontinental clinical trials in pediatric oncology opened over the last decade. Methods: ClinicalTrials.gov was systematically searched to identify all clinical therapeutic trials which opened between 2010 and 2020 and recruited pediatric patients (<18 years) with cancer. Results: Over the last 10 years, 295 (8.7%) of 3383 therapeutic pediatric cancer trials were international and 182 (5.4%) were intercontinental. Most intercontinental trials were phase‐1 or 2, with 25% late‐phase, 65% were sponsored by industry, and North America was involved in 92%. Industry‐sponsored proportionally more phase‐1 trials than academia (41% vs. 25%); conversely, academia sponsored more phase‐2 and late‐phase trials (39% and 31% vs. 36% and 21%, respectively) (p = 0.020). North America–Europe collaboration was predominantly industry sponsored as opposed to North America–Oceania and Europe–Oceania collaboration, more frequently academic (p < 0.0001). Most late‐phase trials (18/20, 90%) focusing on pediatric malignancies were conducted by academic sponsors and 10 of these were conducted by Children's Oncology Group (COG)/National Cancer Institute in the United States and Oceania. There was no significant increase over time of intercontinental trials and a trend for a reduction in academic trials. Conclusions: Despite the relative rarity of childhood malignancies, especially within molecular subtypes, only 5.4% of pediatric cancer trials were intercontinental. The number of intercontinental trials remains small, with no significant increase over the last decade. The ACCELERATE International Collaboration Working Group aims to identify existing hurdles and propose solutions to improve intercontinental collaboration in clinical research for the benefit of children and adolescents with cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Lentiviral Hematopoietic Stem and Progenitor Cell Gene Therapy for Wiskott-Aldrich Syndrome (WAS): Up to 8 Years of Follow up in 17 Subjects Treated Since 2010
- Author
-
Ferrua, Francesca, primary, Cicalese, Maria Pia, additional, Galimberti, Stefania, additional, Giannelli, Stefania, additional, Dionisio, Francesca, additional, Barzaghi, Federica, additional, Migliavacca, Maddalena, additional, Bernardo, Maria Ester, additional, Calbi, Valeria, additional, Tucci, Francesca, additional, Assanelli, Andrea A., additional, Peccatori, Jacopo, additional, Albertazzi, Elena, additional, Clerici, Alessandra G., additional, Salerio, Federica A., additional, Scala, Serena, additional, Basso-Ricci, Luca, additional, Cenciarelli, Sabina, additional, Canarutto, Daniele, additional, Fraschetta, Federico, additional, Bartoli, Antonella, additional, Wolf, Hermann M., additional, Silvani, Paolo, additional, Gattillo, Salvatore, additional, Coppola, Milena, additional, Santoleri, Luca, additional, Villa, Anna, additional, Jones, Russell, additional, Dott, Chris, additional, Grazia Valsecchi, Maria, additional, Ciceri, Fabio, additional, Naldini, Luigi, additional, and Aiuti, Alessandro, additional
- Published
- 2019
- Full Text
- View/download PDF
16. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial
- Author
-
Biondi, A, Gandemer, V, De Lorenzo, P, Cario, G, Campbell, M, Castor, A, Pieters, R, Baruchel, A, Vora, A, Leoni, V, Stary, J, Escherich, G, Li, C, Cazzaniga, G, Cavé, H, Bradtke, J, Conter, V, Saha, V, Schrappe, M, Grazia Valsecchi, M, Biondi, Andrea, Gandemer, Virginie, De Lorenzo, Paola, Cario, Gunnar, Campbell, Myriam, Castor, Anders, Pieters, Rob, Baruchel, André, Vora, Ajay, Leoni, Veronica, Stary, Jan, Escherich, Gabriele, Li, Chi-Kong, Cazzaniga, Giovanni, Cavé, Hélène, Bradtke, Jutta, Conter, Valentino, Saha, Vaskar, Schrappe, Martin, Grazia Valsecchi, Maria, Biondi, A, Gandemer, V, De Lorenzo, P, Cario, G, Campbell, M, Castor, A, Pieters, R, Baruchel, A, Vora, A, Leoni, V, Stary, J, Escherich, G, Li, C, Cazzaniga, G, Cavé, H, Bradtke, J, Conter, V, Saha, V, Schrappe, M, Grazia Valsecchi, M, Biondi, Andrea, Gandemer, Virginie, De Lorenzo, Paola, Cario, Gunnar, Campbell, Myriam, Castor, Anders, Pieters, Rob, Baruchel, André, Vora, Ajay, Leoni, Veronica, Stary, Jan, Escherich, Gabriele, Li, Chi-Kong, Cazzaniga, Giovanni, Cavé, Hélène, Bradtke, Jutta, Conter, Valentino, Saha, Vaskar, Schrappe, Martin, and Grazia Valsecchi, Maria
- Abstract
Background: The EsPhALL2004 randomised trial showed a 10% advantage in disease-free survival for short, discontinuous use of imatinib after induction compared with no use of imatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia receiving Berlin-Frankfurt-Münster chemotherapy and haemopoietic stem-cell transplantation (HSCT). Other contemporary studies showed an advantage from continuous protracted exposure to imatinib, challenging the indications to transplant. The EsPhALL2010 study was designed to assess whether imatinib given from day 15 of induction and continuously throughout chemotherapy led to a different outcome to that obtained in EsPhALL2004, despite decreasing the number of patients having HSCT. Methods: This prospective, intergroup, open-label, single-arm clinical trial (EsPhALL2010) was done at 11 study groups across Europe, Chile, and Hong Kong. Patients aged 1–17 years with the translocation t(9;22)(q34;q11) who were recruited into national front-line trials for acute lymphoblastic leukaemia were eligible for this trial. Patients with abnormal renal or hepatic function or an active systemic infection were ineligible. Patients received imatinib 300 mg/m2 continuously from day 15 of induction during chemotherapy. Eligibility to HSCT depended on early morphological response and minimal residual disease. Imatinib was recommended throughout the first year after transplant. The co-primary endpoints were event-free survival and overall survival. All analyses were done in the intention-to-treat population. The trial is registered with the European Clinical Trials Database (EudraCT 2004-001647-30) and with ClinicalTrials.gov (NCT00287105) and is completed. Findings: 158 patients were screened for eligibility, of whom 155 were enrolled between Jan 1, 2010, and Dec 31, 2014. 151 (97%) patients achieved first complete remission after induction and four after the consolidation phase, with 102 (66%) patients categorised as good ri
- Published
- 2018
17. CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
- Author
-
Hunger, Stephen P., primary, Saha, Vaskar, additional, Devidas, Meenakshi, additional, Grazia Valsecchi, Maria, additional, Gastier Foster, Julie, additional, Cazzaniga, Gianni, additional, Reshmi, Shalini C., additional, Borowitz, Michael, additional, Moorman, Anthony, additional, Heerema, Nyla A., additional, Carroll, Andrew J., additional, Barnette, Phillip, additional, Gramatges, M. Monica Monica, additional, Maloney, Kelly, additional, Sun, Weili, additional, Swanink, Rene, additional, Termuhlen, Amanda, additional, Loh, Mignon L., additional, Raetz, Elizabeth A., additional, Silverman, Lewis B., additional, Schrappe, Martin, additional, Schultz, Kirk R., additional, Slayton, William, additional, Healey, Diane, additional, and Biondi, Andrea, additional
- Published
- 2017
- Full Text
- View/download PDF
18. The SIPI for measuring complexity in nursing care: evaluation study
- Author
-
Chantal Moiset, Grazia Valsecchi Maria, Paola Rebora, Ilaria D'Ilio, Stefania Galimberti, Stefania Di Mauro, Roberto Viganò, Galimberti, S, Rebora, P, DI MAURO, S, D'Ilio, I, Viganò, R, Moiset, C, and Valsecchi, M
- Subjects
medicine.medical_specialty ,Nursing staff ,Nursing care evaluation ,business.industry ,MED/45 - SCIENZE INFERMIERISTICHE GENERALI, CLINICHE E PEDIATRICHE ,Nursing assessment ,Nursing ,Workload ,Nursing Staff, Hospital ,Nursing Outcomes Classification ,Nursing care ,Nursing care, Nursing assessment, Needs assessment, Patient-centred care, Nursing Staff ,Italy ,ROC Curve ,Family medicine ,Surveys and Questionnaires ,Needs assessment ,Medicine ,Nursing Minimum Data Set ,business ,General Nursing ,Primary nursing - Abstract
Background The traditional model for nursing staff management widely used in Italian hospitals assumes that diagnosis determines the amount of nursing required, but this has been widely criticized. In order to quantify and monitor the fluctuation of the complexity in nursing care, a questionnaire, called SIPI ( Sistema Informativo della Performance Infermieristica ), that is based on the care needs expressed by the patients, has been proposed in the Monza Hospital. Design A group of trained nurses were asked to indicate their own perception of the level of nursing day-care complexity provided to each patient and then to complete the SIPI. Settings The Monza Hospital coordinated this multi-centre study that involved 25 Hospitals of North Italy. Participants Each hospital contributed with a minimum of three units, at least one for each area of intensity of clinical care, as defined by health regulators. All adult in-patients being in the units from at least 24h were included in the survey. Psychiatric wards, neonatology, intensive and semi-intensive care wards were non considered. Methods A group of nurses trained with the use of SIPI completed the questionnaires based on the nursing file of performed activities. Before filling the questionnaire, the nurses were asked to indicate their perception of the level of complexity of the day-care provided to each patient. In order to calculate the SIPI scores that discriminate different nurse complexity levels, a ROC analysis and the multinomial logistic regression model were used, considering the perceived complexity as the standard of reference. Results The nursing day-care complexity was measured in 115 wards, for a total of 17,803 completed questionnaires. Nursing complexity was roughly the same in areas of different intensity of clinical care, both according to perception and as measured by SIPI. A cut-off of 49.2 was identified as optimal to distinguish two classes of complexity with a good performance (80% of specificity, 85% of sensitivity). Conclusions The SIPI was shown to be a simple and useful tool that may be adopted in the future for an optimal allocation of nursing resources. The results of this study confirmed that elevated intensity of care from the clinical perspective does not necessarily correspond to high nursing complexity.
- Published
- 2011
19. Long term survivors of childhood cancer: Cure and care
- Author
-
Haupt, Riccardo, primary, Spinetta, John J., additional, Ban, Irina, additional, Barr, Ronald D., additional, Beck, Joern D., additional, Byrne, Julianne, additional, Calaminus, Gabriele, additional, Coenen, Eva, additional, Chesler, Mark, additional, D’Angio, Giulio J., additional, Eiser, Christine, additional, Feldges, Andreas, additional, Gibson, Faith, additional, Lackner, Herwig, additional, Masera, Giuseppe, additional, Massimo, Luisa, additional, Magyarosy, Edina, additional, Otten, Jacques, additional, Reaman, Gregory, additional, Grazia Valsecchi, Maria, additional, Veerman, Anjo J.P., additional, Penn, Anthony, additional, Thorvildsen, Anne, additional, van den Bos, Cor, additional, and Jankovic, Momcilo, additional
- Published
- 2007
- Full Text
- View/download PDF
20. Maternal perception of excess weight in children: A survey conducted by paediatricians in the province of Milan
- Author
-
Genovesi, Simonetta, primary, Giussani, Macro, additional, Faini, Andrea, additional, Vigorita, Federico, additional, Pieruzzi, Federico, additional, Grazia Strepparava, Maria, additional, Stella, Andrea, additional, and Grazia Valsecchi, Maria, additional
- Published
- 2007
- Full Text
- View/download PDF
21. Liver-Directed Adeno-Associated Virus–Mediated Gene Therapy for Mucopolysaccharidosis Type VI
- Author
-
Nicola Brunetti-Pierri, M. D. 1 2, Rita Ferla, Ph. D. 1, 2, Virginia Maria Ginocchio, M. D., Alessandro Rossi, Ph. D. 2, Simona Fecarotta, Ph. D. 3, Roberta Romano, M. D. 2, Giancarlo Parenti, Yilmaz Yildiz, Ph. D. 4, Stefano Zancan, M. Sc. 5, Valentina Pecorella, M. Sc. 1, Margherita Dell’Anno, Mafalda Graziano, Marialuisa Alliegro, Generoso Andria, Francesca Santamaria, Raffaella Brunetti-Pierri, Ph. D. 6, Francesca Simonelli, M. D. 6, Vincenzo Nigro, M. D. 1 7, Maria Vargas, M. D. 8, Giuseppe Servillo, Francesco Borgia, M. D. 9, Ernesto Soscia, M. D. 10, Marco Gargaro, Ph. D. 11, Silvia Funghini, Ph. D. 12, Novella Tedesco, M. Sc. 13, Pierre Romain Le Brun, Charles A. Rupar, Ph. D., F. C. C. M. G. 15, Chitra Prasad, M. D. F. R. C. P., Mar O’Callaghan, Ph. D. 16, John J. Mitchell, F. R. C. P. 17, Olivier Danos, Ph. D. 19, Jean-Brice Marteau, Ph. D. 20, Stefania Galimberti, Ph. D. 21, Maria Grazia Valsecchi, Philippe Veron, Ph. D. 13, Federico Mingozzi, Francesca Fallarino, Giancarlo la Marca, Pharm. Sc. 12, H. Serap Sivri, M. D. 4, and Alberto Auricchio, M. D. 1, BRUNETTI PIERRI, Nicola, 1 2, M. D., Ferla, Rita, h. D. 1., P, Ginocchio, virginia maria, D., M., Rossi, Alessandro, h. D. 2., P, Fecarotta, Simona, h. D. 3., P, Romano, Roberta, D. 2., M., Parenti, Giancarlo, Yildiz, Yilmaz, h. D. 4., P, Zancan, Stefano, Sc. 5., M., Pecorella, Valentina, Sc. 1., M., Dell’Anno, Margherita, Graziano, Mafalda, Alliegro, Marialuisa, Andria, Generoso, Santamaria, Francesca, Brunetti-Pierri, Raffaella, h. D. 6., P, Simonelli, Francesca, D. 6., M., Nigro, Vincenzo, 1 7, M. D., Vargas, Maria, D. 8., M., Servillo, Giuseppe, Borgia, Francesco, D. 9., M., Soscia, Ernesto, 10, M. D., Gargaro, Marco, 11, Ph. D., Funghini, Silvia, 12, Ph. D., Tedesco, Novella, 13, M. Sc., Romain Le Brun, Pierre, Rupar, Charles A., h. D., P, 15, F. C. C. M. G., Prasad, Chitra, D. F. R. C. P., M., O’Callaghan, Mar, 16, Ph. D., Mitchell, John J., 17, F. R. C. P., Danos, Olivier, 19, Ph. D., Marteau, Jean-Brice, 20, Ph. D., Galimberti, Stefania, 21, Ph. D., Grazia Valsecchi, Maria, Veron, Philippe, 13, Ph. D., Mingozzi, Federico, Fallarino, Francesca, la Marca, Giancarlo, 12, Pharm. Sc., Serap Sivri, H., D. 4., M., Alberto Auricchio, And, and D. 1., M.
- Published
- 2022
22. Utility of precipitating antibody testing in the diagnostic evaluation of chronic hypersensitivity pneumonia.
- Author
-
Giacomi F, Andreano A, Faverio P, Biffi A, Ruvolo L, Sverzellati N, Grazia Valsecchi M, and Pesci A
- Abstract
Background: Chronic hypersensitivity pneumonitis (HP), in its progressive fibrotic form, is difficult to distinguish from other fibrosing interstitial lung diseases (ILD), particularly idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP). The role of serum precipitating antibodies in the diagnosis of fibrosing ILD has not been discussed in recent clinical practice guidelines. Objectives: The aim of this study is to assess the role of precipitins in the diagnosis of non pre-selected cases of fibrosing ILD. Methods: Clinical records of 108 consecutive patients referred for presumptive fibrosing ILD to our institution were retrospectively assessed for exposure history, serum precipitins, other diagnostic examinations, and multidisciplinary diagnosis (MDD). Their high resolution computed tomography (HRCT) images were blindly and prospectively re-assessed. We estimated sensitivity and specificity of precipitins against MDD and, to account for incorporation bias, we used two composite reference standards (CRSs), having exposure history and HRCT as component tests. Results: Definitive diagnosis achieved through MDD were chronic HP (17% of cases), NSIP (42%), IPF (18%) and others (23%). For serum precipitins, we estimated a sensitivity of 72% and a specificity of 68% using MDD as the reference standard. Sensitivity against the AND-CRS was 55%, while specificity against the OR-CRS was 61%. On the basis of this results, we can expect true sensitivity of precipitins lying between 55 and 72% and specificity between 61 and 68%. Conclusions: Serum precipitating antibodies did not result as having a relevant role in the diagnostic approach to chronic HP (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 149-155) ., (Copyright: © 2017.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.